Advertisement

CNS Drugs

, Volume 31, Issue 7, pp 603–603 | Cite as

Erratum to: Health-Related Quality of Life in Patients with Multiple Sclerosis: Impact of Disease-Modifying Drugs

  • Peter Joseph JongenEmail author
Erratum

1 Erratum to: CNS Drugs DOI 10.1007/s40263-017-0444-x

An Online First version of this article was made available online at http://link.springer.com/journal/40263/onlineFirst/page/1 on 12 June 2017. A number of errors were subsequently identified in the article, and the following corrections should be noted:

Page 2, column 1, line 8: The text, which previously read:

" … INFβ-1b, pegylated INFβ-1a …" should read:

“… IFNβ-1b, pegylated IFNβ-1a …”

Page 6, Table 2, ‘Outcome’ column, line 1: The text, which previously read:

“… LMSQOL score …” should read:

“… LMSQoL score …”

Page 9, column 1, line 3: The text, which previously read:

" … INFβ-1a …” should read:

“… IFNβ-1a …”

Page 11, column 2, line 11: The text, which previously read:

“ … INFβ …” should read:

“… IFNβ …”

Page 11, column 2, line 20: The text, which previously read:

“ … INFβ-1a …” should read:

“… IFNβ-1a …”

Copyright information

© Springer International Publishing AG  2017

Authors and Affiliations

  1. 1.Department of Community and Occupational MedicineUniversity Medical Center GroningenGroningenThe Netherlands
  2. 2.MS4 Research InstituteNijmegenThe Netherlands

Personalised recommendations